Tool
Tirzepatide Dose-Surcharge Comparison
Tirzepatide dosing escalates, so the price you enrol at is often not the price you pay at a maintenance dose. This tool models what a dose-related surcharge does to your total cost, which can reverse which provider is cheaper within months. Dose-coverage terms are unverified across our provider dataset.
Key takeaways
- The dose you enrol at is rarely the dose you stay on, so enrolment pricing can mislead.
- A surcharge applied above a dose threshold can reverse which provider is cheapest.
- Dose-coverage terms are unverified for every provider in our dataset.
- Ask specifically what the price becomes at 10 mg and 15 mg before committing.
- This tool runs in your browser; nothing you enter is transmitted or stored.
| What it models | Cost impact of a dose-related surcharge over time |
|---|---|
| Why it matters | Escalation means the enrolment dose is temporary |
| Dataset status | Dose-coverage terms unverified for all providers |
| Question to ask | What is the price at 10 mg and at 15 mg? |
| Data handling | Runs entirely in your browser |
Model a dose surcharge
Why is dose coverage the question people forget?
Because at enrolment you are on a starting dose and the question feels hypothetical. By month four or six it is not hypothetical at all, and by then you may have prepaid a commitment. A surcharge of $50 monthly applied for twenty of twenty-four months is $1,000 — frequently more than the difference that led someone to choose one provider over another.
What should you ask before enrolling?
What the total monthly cost becomes at 10 mg and at 15 mg, in writing. Not whether higher doses are 'available' — what they cost. A provider that cannot answer that clearly before payment has told you something about how the pricing works.
Related: Higher-dose providers · True-cost calculator
What do the verified rates look like?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
What does this page cover, and what does it deliberately leave out?
This page addresses Dose tiers, included maximum and surcharge and recurring cost, organised around the primary question of tirzepatide dose surcharge. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Dose tiers | Covered on this page | Regulatory or policy source |
| Included maximum | Covered on this page | Regulatory or policy source |
| Surcharge and recurring cost | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the provider's own quotation |
What are the limits of what this page can tell you?
Every page on this site rests on a specific figures you enter, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the provider's own quotation.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide dose surcharge.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Do all providers charge more for higher doses?
Some hold price flat and some apply surcharges. This term is unverified for every provider in our dataset.
How much can a surcharge change my total?
Substantially — a $50 monthly surcharge over twenty months is $1,000, often more than the difference between providers at enrolment.
What should I ask before signing up?
What the total monthly cost is at 10 mg and 15 mg, in writing.
Is my input stored?
No. The tool runs in your browser only.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.